BioSpace News Archive

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Corporation”) today announced that its wholly owned subsidiary, IntelGenx Corp. (“IntelGenx”), a leader in pharmaceutical films, has agreed to the terms of a strategic partnership with atai Life Sciences (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, including an equity investment by atai,

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck’s immune check point inhibitor, KEYTRUDA, + Pfizer’s androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications receiving standard of care, including remdesivir and/or dexamethasone,

Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), is pleased to announce its lead compound RECCE® 327 (R327) has been added to The Pew Charitable Trusts’ annual list of Non-traditional Products in Development to Combat Bacterial Infections identifying new antibiotic treatments in development worldwide.

Biotech Acquisition Company (NASDAQ: BIOTU) (the “Company”) announced that, commencing March 18, 2021 , holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (“Class A Ordinary Shares”) and warrants included in the units. No fractional warrants will be issue

Leatt Corporation, a developer and marketer of protective equipment and ancillary products for many forms of sports, especially extreme high-velocity sports, announced that its X-Frame Hybrid Knee Brace has received a 2021 Powersports Business Nifty 50 Award from the editors of Powersports Business.

Sobi™, a North American affiliate of the international biopharmaceutical company Swedish Orphan Biovitrum AB (publ) (Sobi®), dedicated to rare diseases, in partnership with the Platelet Disorder Support Association (www.pdsa.org PDSA), a leading immune thrombocytopenia (ITP) advocacy organization in North America, today announced the launch of florio®ITP

The Company’s Assembling of this Sales Force Coincides with Launch of its Increased Tauri-Gum™ CBD & CBG Infusion Concentrations (25mg/per Serving)

Both 5-MeO-DMT and DMT possess unique pharmacodynamic and pharmacokinetic properties compared to other clinically studied psychedelics, including a shorter duration of action, which may help reduce the amount of time a patient would spend in the clinic during psychedelic-assisted psychotherapy.

Relay is a founding shareholder of Glow and recently added to its position by participating in Glow’s RTO financing on February 9, 2021, which was oversubscribed at over $5.1 million raised.